Clinical Core (Core A) is responsible for centralized functions that provide the foundation for the proposed research in this Program Project. The 4 functions of the Core are (1) to provide access to patients with ANCA disease throughout their disease course for recruitment into the proposed studies, (2) to collect, process and store biologic samples from patients at various disease stages as well as from family members and controls, (3) monitor and manage information on the long-term outcomes in patients with ANCA disease using standard definitions, and, (4) manage, integrate and process the medical and biologic information from components of all projects, which includes management of the integrated database, and statistical analyses and interpretation of results. Careful clinical characterization and long-term follow-up of patients with ANCA disease is a major effort that requires an experienced team of investigators and staff as put together by this Core. The Core provides uniform identification of remission and relapses of the disease, which facilitates the coordination of biologic sample collections during these different disease stages. Identification of patients with various levels of disease activity is also critical for determination of those eligible for proposed trials and clinical studies. The collection of biologic samples from family members of patients with ANCA disease and healthy controls can also be accomplished as required by Core A. Core A has well established methods for the collection of samples in conjunction with a database system for storage and identification of multiple samples among patients. The database allows for the unique information required for each study to be easily linked with clinical information. Core A will also provide support needed for study design and statistical analyses throughout the proposed program project, with the goal of assisting all projects in the successful and timely publication of results. This Core has been in existence under the leadership of Susan L. Hogan, PhD since the original cycle of funding for this Program Project in 1999. The overall experience and dedication of the faculty and staff of Core A will continue to bring a strong resource on which each project can depend and can, therefore, successfully launch their laudable scientific goals.

Public Health Relevance

This Core provides centralized support to all 4 of the proposed research projects within the Program Project, 'ANCA Glomerulonephritis: from Molecules to Man'. The Core provides the infrastructure and centralized systems for enrolling patients into the research projects, determining the disease status of patients with ANCA-related disease, collecting biologic samples, and storage and analysis of all research data.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK058335-13
Application #
8566060
Study Section
Special Emphasis Panel (ZDK1-GRB-R (M1))
Project Start
2000-09-01
Project End
2015-07-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
13
Fiscal Year
2012
Total Cost
$221,974
Indirect Cost
$71,992
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Weiner, Maria; Bjørneklett, Rune; Hrušková, Zdenka et al. (2018) Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant :
van Daalen, Emma E; Jennette, J Charles; McAdoo, Stephen P et al. (2018) Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clin J Am Soc Nephrol 13:63-72
Thorpe, Carolyn T; Thorpe, Joshua M; Jiang, Tao et al. (2018) Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis. Semin Arthritis Rheum 47:507-519
McCall, A Scott; Bhave, Gautam; Pedchenko, Vadim et al. (2018) Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes. J Am Soc Nephrol 29:2619-2625
Alba, Marco A; Jennette, J Charles; Falk, Ronald J (2018) Pathogenesis of ANCA-Associated Pulmonary Vasculitis. Semin Respir Crit Care Med 39:413-424
Alba, Marco A; Flores-Suárez, Luis Felipe; Henderson, Ashley G et al. (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16:722-729
Cortazar, Frank B; Pendergraft 3rd, William F; Wenger, Julia et al. (2017) Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 69:1045-1053
Payan Schober, Fernanda; Jobson, Meghan A; Poulton, Caroline J et al. (2017) Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. Am J Nephrol 45:248-256
Jones, Britta E; Yang, Jiajin; Muthigi, Akhil et al. (2017) Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. J Am Soc Nephrol 28:1175-1187
Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066

Showing the most recent 10 out of 86 publications